Fri, Apr 18, 2014, 8:04 AM EDT - U.S. Markets closed for Good Friday

Recent

% | $
Quotes you view appear here for quick access.

Genomic Health Inc. Message Board

terry_amln 19 posts  |  Last Activity: 16 hours ago Member since: Oct 25, 2010
  • Those bios that are getting a kick are setting up for the pump and dump.Genomic Health has been here for a year. I've been here for 4. May 5 for rev if we do not hear something sooner Good Luck

  • NICE Recommends Genomic Health's Oncotype DX® Test To Guide Chemotherapy Treatment Decisions For Qualified Early-Stage Invasive Breast Cancer Patients
    NICE's Recommendation of Oncotype DX® Test is an Important Milestone in Delivering Personalized Medicine to More UK Patients
    the National Institute for Health and Care Excellence (NICE) in the United Kingdom has issued its final guidance recommending Oncotype DX® as the only multi-gene breast cancer test for use in clinical practice to guide chemotherapy treatment decisions for patients with early-stage, hormone receptor-positive, invasive breast cancer. Consistent with leading international breast cancer treatment guidelines, including ASCO®, NCCN®, ESMO ® and St. Gallen, NICE's recommendation recognizes the unparalleled evidence of the clinical validity of the Oncotype DX test and its ability to enable physicians and their patients to make more informed, individualized decisions.

    "It is encouraging to see growing recognition of the value of genomic testing. Its provision has enhanced the care of breast cancer patients around the world and it will now be available as an option in the UK," said David Miles, M.D., medical oncologist at Mount Vernon Cancer Centre, Northwood, Middlesex, United Kingdom. "NICE's recommendation for the use of Oncotype DX in the UK is an important step forward, enabling physicians and patients to make better-informed treatment decisions based on the biology of an individual patient's breast cancer."

    To date, more than 1,500 women in the UK have utilized the Oncotype DX test to help guide their treatment decisions. Breast cancer is the most commonly diagnosed cancer in women, with almost 50,000 people diagnosed each year in the UK. Most of these patients are diagnosed with early-stage, invasive breast cancer and a significant nu

  • terry_amln by terry_amln Apr 15, 2014 10:46 PM Flag

    Prostate test will make the 1/4 B breast and colon test look like chump change. after a year the wheels move slowly with advances like these.

  • Reply to

    GHDX announces more data supporting its use

    by terry_amln Mar 20, 2014 9:14 AM
    terry_amln terry_amln Apr 15, 2014 10:42 PM Flag

    Genomic Health announces presentation of new data further supporting use of Oncotype DX in Europe; physician survey reveals substantial differences in chemotherapy treatment recommendations (GHDX) :
    Co announced the presentation of multiple Oncotype DX breast cancer studies at the 9th European Breast Cancer Conference, which takes place March 19-21 in Glasgow, Scotland, United Kingdom. New data will include an independently conducted physician survey that underscores the need for broader availability of standard predictive genomic testing, like Oncotype DX, to help better inform chemotherapy treatment decisions in early-stage breast cancer patients in Europe. Additional studies showcasing the unsurpassed volume and consistency of clinical validation, clinical utility and health-economics evidence supporting the use of Oncotype DX will also be presented at the meeting.

  • Reply to

    GHDX announces more data supporting its use

    by terry_amln Mar 20, 2014 9:14 AM
    terry_amln terry_amln Apr 15, 2014 10:27 PM Flag

    Genomic Health announces presentation of new data further supporting use of Oncotype DX in Europe; physician survey reveals substantial differences in chemotherapy treatment recommendations (GHDX) :
    Co announced the presentation of multiple Oncotype DX breast cancer studies at the 9th European Breast Cancer Conference, which takes place March 19-21 in Glasgow, Scotland, United Kingdom. New data will include an independently conducted physician survey that underscores the need for broader availability of standard predictive genomic testing, like Oncotype DX, to help better inform chemotherapy treatment decisions in early-stage breast cancer patients in Europe. Additional studies showcasing the unsurpassed volume and consistency of clinical validation, clinical utility and health-economics evidence supporting the use of Oncotype DX will also be presented at the meeting

  • I have proxys to my account who post for laughs,young teens who wonder if some adults really act like this. I rarely spend more than a few minutes here, like this mornings sell call, or second cup of cafe.
    Unfortunately the info that is supposedly me is not. The numbers posted could possibly offend or even frighten families who have nothing to do with this message board shows the extent these mental midgets
    will go.This board is clearly important to them( what a life(sic)
    Sometimes I shake my head at their investment stupidity but this is not funny - it's sick

  • I have proxys to my account who post for laughs,young teens who wonder if some adults really act like this. I rarely spend more than a few minutes here, like this mornings sell call, or second cup of cafe.
    Unfortunately the info that is supposedly me is not. The numbers posted could possibly offend or even frighten families who have nothing to do with this message board shows the extent these mental midgets
    will go.This board is clearly important to them( what a life(sic)
    Sometimes I shake my head at their investment stupidity but this is not funny - it's sick

  • I have proxys to my account who post for laughs,young teens who wonder if some adults really act like this. I rarely spend more than a few minutes.here, like this mornings sell call, or second cup of cafe.
    Unfortunately the info that is supposedly me is not. The numbers posted could possibly offend or even frighten families who have nothing to do with this message board shows the extent these mental midgets
    will go.This board is clearly important to them( what a life(sic)
    Sometimes I shake my head at their investment stupidity but this is not funny - it's sick

  • Genomic Health announces presentation of new data further supporting use of Oncotype DX in Europe; physician survey reveals substantial differences in chemotherapy treatment recommendations (GHDX) :
    Co announced the presentation of multiple Oncotype DX breast cancer studies at the 9th European Breast Cancer Conference, which takes place March 19-21 in Glasgow, Scotland, United Kingdom. New data will include an independently conducted physician survey that underscores the need for broader availability of standard predictive genomic testing, like Oncotype DX, to help better inform chemotherapy treatment decisions in early-stage breast cancer patients in Europe. Additional studies showcasing the unsurpassed volume and consistency of clinical validation, clinical utility and health-economics evidence supporting the use of Oncotype DX will also be presented at the meeting.

  • terry_amln terry_amln Mar 5, 2014 3:20 PM Flag

    speculating at least 5 years out with nothing to go on is the work of a clown. The work being done in the genetics field regarding antibiotic resistance dwarfs drugs.

  • terry_amln terry_amln Feb 18, 2014 1:28 PM Flag

    While the FDA has done some things in recent years to improve how it reviews companion diagnostics that help guide treatments for cancer, there is still a vast swath of the diagnostics world that is lightly regulated at best. It allows for skepticism about these tests to fester among payers, and spawns fear among investors who worry the payers will never pay. “We’d like a process that has clarity and some certainty around how you do it,” Popovits says. “When you develop a drug, you go through Phase I, II, and III, and then you go to FDA. They say ‘yea or nay,’ and then you get reimbursed. That’s a process we need.”

    For sure, the idea of tough, consistent FDA regulation of diagnostics isn’t new. The FDA has been making noises for years about getting more aggressive about regulating “high-risk” laboratory-developed tests (LDTs) that influence big healthcare decisions like how to treat a cancer patient—where the consequences of a false test can be dire. AdvaMed, the trade group for medical device and diagnostic companies, has said the FDA should regulate “higher-risk” tests. Industry leaders Brook Byers of Kleiner Perkins Caufield & Byers and Mara Aspinall of Roche’s Ventana Medical Systems unit co-wrote an op-ed for the Boston Globe in 2011 about why they think the FDA should bring more rigorous regulation to the diagnostics business.

    “For one thing, both payers and physicians need and deserve to have confidence that the advanced diagnostic methods being used are reliable and accurate,” Byers and Aspinall wrote. “As it stands today, diagnostics are regulated by a variety of state and federal agencies, but there are, as yet, no clear policies in place for the approval of new molecular diagnostics.”

  • xxxx://xxx.xconomy.coX/national/2014/02/17/molecular-diagnostics-are-in-a-rut-the-industry-needs-the-fda/
    Some of the more exciting ideas in biotech are coming up in molecular diagnostics. There’s cool science at work. A number of tests have potential to cut down on overtreatment, reduce waste in healthcare, and give physicians clever new ideas on how to help patients.

    But this industry, which accounts for less than 2 percent of healthcare spending, is stuck in neutral. If it’s ever going to grow into a bigger business that delivers lots of valuable information about health, the molecular diagnostics industry needs a tough, science-minded, credible regulator. It needs a thorough, predictable, and efficient third party who can comb through complex data sets and say with confidence what’s real, what’s clinically meaningful, and what’s BS.

    Physicians, patients, and payers aren’t just going to do this by themselves.
    Just like the pharmaceutical industry, the diagnostics world needs a strong FDA.

    “We have to have some kind of pathway that gets rid of the uncertainty hanging over the whole space now,” says Kim Popovits, CEO of Redwood City, CA-based Genomic Health (NASDAQ: GHDX), a leader in molecular diagnostics.Kim Popovits, CEO of Genomic Health

  • Reply to

    Zacks

    by sblum2000 Feb 13, 2014 4:10 PM
    terry_amln terry_amln Feb 13, 2014 5:41 PM Flag

    Zacks is nothing short of a paid stoolie. I assure you Zacks UBS and the other that downgraded are helping those who are long Genomic Health.Selling at 3x to revenues with no debt Gemonic health, Felix Julian and myself only add when they push it down. Steve Burrill thinks this company is one of the best -investments - in biotech.We dont care what the price is today - we care what it is when we sell Good Luck

  • Reply to

    PT this year 56+

    by frankyassissi Feb 3, 2014 8:46 AM
    terry_amln terry_amln Feb 4, 2014 7:31 PM Flag

    earnings were just ok .FY14 guidance to ($0.95)-(0.75) EPS & revenue guidance to $278-286 million.Although growth is steady and co is investing in the future,Wall street wants more.I do suspect an attack - no doubt a buying opp if you are long a couple of years.Myriad Genetics acquired Crescendo Bioscience and is up.... strong.consolidation in this sector (and the Bakers never take a cheap price unless GHDX goes private). I only see your 56 if there is a takeover Good Luck

  • Genomic Health Announces Results of Oncotype DX(R) Colon Cancer Studies Presented at 2014 American Society of Clinical Oncology Gastrointestinal Cancer (ASCO GI) Symposium

    New data show real-life impact of Oncotype DX on treatment decisions, underscore clinical validity and utility of the test GHDX) today announced results from the Oncotype DX® colon cancer test studies that were recently presented at the 2014 American Society of Clinical Oncology Gastrointestinal Cancer Symposium (ASCO GI). Presentations highlighted the robust body of clinical evidence for the Oncotype DX colon cancer test and its real-life impact on patient and physician treatment decisions, underscoring the practice-changing value of this test.
    Prospective study demonstrated real-life impact on physician and patient treatment decisions
    Through an analysis of physician recommendations and patient treatment preferences before and after receiving the Oncotype DX colon cancer test results, this study demonstrated that the test greatly increased concordance between physician and patient treatment choice (from 66 percent to 96 percent). Furthermore, the evaluation showed that the quantitative information provided by the Recurrence Score® result influenced a majority of patients' treatment decisions (85 percent) and physicians' treatment recommendations (69 percent), and it increased physicians' confidence in their own recommendations (84 percent). Patients' anxiety was also significantly reduced, which may improve adherence to their treatment plan and ultimately lead to better health outcomes.

    "The additional information provided by the Oncotype DX test enables me and my patients to make better informed decisions about their individual treatment," said Steven Alberts, M.D., chair of the Division of Medical Oncology at Mayo Clinic Cancer Center, Roche

  • Reply to

    1600 @29.86 3 lots

    by terry_amln Jan 27, 2014 10:22 AM
    terry_amln terry_amln Jan 28, 2014 9:14 AM Flag

    my avg is still in the teens.

  • Reply to

    1600 @29.86 3 lots

    by terry_amln Jan 27, 2014 10:22 AM
    terry_amln terry_amln Jan 27, 2014 10:31 AM Flag

    and again @.50 .The dont care where it is going short term.and neither do I except to add
    Good Luck

  • terry_amln by terry_amln Jan 27, 2014 10:22 AM Flag

    Thank you.

  • As frank will and Rosie has, I am NEITHER of these posters

GHDX
26.81-0.02(-0.07%)Apr 17 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Weibo Corporation
NasdaqGSThu, Apr 17, 2014 4:00 PM EDT
Triangle Petroleum Corporation
NYSE MKTThu, Apr 17, 2014 4:01 PM EDT